Spruce Biosciences Appoints New Chief Medical Officer

What Happened
Spruce Biosciences, Inc. announced on July 27, 2026 (8-K filing) that it has appointed Adrian Quartel, M.D., FFPM, as its Chief Medical Officer. Dr. Quartel replaces Dr. Kirk Ways, who had been serving as Interim Chief Medical Officer and will continue to serve on the company’s Board of Directors. The filing highlights Dr. Quartel’s more than 25 years of experience in clinical development, pharmacovigilance, and medical affairs, including leadership roles at Zevra Therapeutics, Acer Therapeutics, Adamas Pharmaceuticals, and BioMarin Pharmaceutical.

Key Details

• Appointment date: July 27, 2026 (8-K filed) — Adrian Quartel, M.D., FFPM named Chief Medical Officer.
• Interim CMO transition: Dr. Kirk Ways steps down as Interim CMO but remains a Board member.
• Experience highlights: 25+ years in the pharmaceutical industry; prior CMO roles at Zevra, Acer, and Adamas; Group VP Global Medical Affairs at BioMarin.
• Track record: Led launches of multiple rare-disease enzyme replacement therapies (examples cited: NAGLAZYME®, VIMIZIM®, Brineura®). Educational credentials include an M.D. from Erasmus University and board certification in pharmaceutical medicine (UK GMC).

Why It Matters
This is an executive leadership change (Item 5.02) that affects Spruce’s clinical and medical strategy execution. Hiring an experienced CMO with a history of advancing and launching therapies for rare diseases could strengthen the company’s clinical development and regulatory capabilities—key areas for a biotech focused on specialty or rare-disease treatments. Investors should note the continuity on the Board with Dr. Ways remaining a director and may watch for future company communications about clinical programs and regulatory plans under the new CMO.